“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.
In this video, Ruchika Talwar, MD, shares the take-home message from the recent Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.